Brief: Plus Therapeutics Secures National Coverage Agreement With Humana For Cnside® Cerebrospinal Fluid Assay For Metastatic Cns Cancer
20/11/2025 13:14
Humana Inc HUM.N: PLUS THERAPEUTICS SECURES NATIONAL COVERAGE AGREEMENT WITH HUMANA FOR CNSIDE® CEREBROSPINAL FLUID ASSAY FOR METASTATIC CNS CANCER Source text: ID:nGNX4wwSmR Further company coverage: HUM.N
Recent news on Cerenome
See all newsBrief: Cerenome Secures In-Network Agreement With Florida Blue For Cnside® Csf Tumor Cell Enumeration And Molecular Profile Tests
Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cerenome Secures In-Network Agreement With Health Care Service Corporation
Plus Therapeutics Inc expected to post a loss of 91 cents a share - Earnings Preview
Brief: Plus Therapeutics Secures Regional Coverage Agreement With Medical Mutual For CNSide Cerebrospinal Fluid Assay For Metastatic CNS Cancer